Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 5
2011 3
2012 2
2013 2
2014 2
2015 2
2016 5
2017 1
2018 5
2019 3
2020 5
2021 2
2022 4
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Sacher A, et al. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. N Engl J Med. 2023. PMID: 37611121 Free article. Clinical Trial.
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.
Semeniuk-Wojtaś A, Poddębniak-Strama K, Modzelewska M, Baryła M, Dziąg-Dudek E, Syryło T, Górnicka B, Jakieła A, Stec R. Semeniuk-Wojtaś A, et al. Among authors: stec r. Cancer Immunol Immunother. 2023 Jul;72(7):1971-1989. doi: 10.1007/s00262-023-03376-9. Epub 2023 Mar 16. Cancer Immunol Immunother. 2023. PMID: 36928373 Free PMC article. Review.
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Desai J, et al. Among authors: stec r. Nat Med. 2024 Jan;30(1):271-278. doi: 10.1038/s41591-023-02696-8. Epub 2023 Dec 5. Nat Med. 2024. PMID: 38052910 Free PMC article. Clinical Trial.
The immune landscape of hepatocellular carcinoma-where we are?
Gryziak M, Wozniak K, Kraj L, Rog L, Stec R. Gryziak M, et al. Among authors: stec r. Oncol Lett. 2022 Sep 27;24(5):410. doi: 10.3892/ol.2022.13530. eCollection 2022 Nov. Oncol Lett. 2022. PMID: 36245826 Free PMC article. Review.
The role of Tau protein in resistance to paclitaxel.
Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B, Szczylik C. Smoter M, et al. Among authors: stec r. Cancer Chemother Pharmacol. 2011 Sep;68(3):553-7. doi: 10.1007/s00280-011-1696-7. Epub 2011 Jun 29. Cancer Chemother Pharmacol. 2011. PMID: 21713447 Free PMC article. Review.
47 results